In recent years, the understanding regarding the role of epigenetic factors has been improved. Epigenetic research has been generally determined by technological advancement, remarkably high-throughput sequencing technologies. In spite of the fact that technologies have been improved and have been responsible for the advances in the field, several challenges remain.
Our 5th Annual Epigenetics- Digital Conference will discuss the solutions to challenges like, drug discovery, identification of molecular inhibitors, gene modification and analysis.
The digital conference is scheduled on 21st & 22nd May 2020, which is one of the unique platform discussing about epigenetics based clinical development and combinational therapies, with a special emphasis on transcriptional analysis and molecular profiling.
Professor Emeritus , Queens University Belfast
Chief Experimental Pharmacology Unit Department of, Istituto Nazionale tumori G. Pascale
Professor Emeritus , Queens University Belfast
Chief Experimental Pharmacology Unit Department of, Istituto Nazionale tumori G. Pascale
Lecturer in Epigenetics, University of Southampton
University of Groningen, Faculty of MedicalSciences
VP Head of Adaptive Immunity RU, Research, GSK
Group Leader , Josep Carreras Leukaemia Institute
Senior Lecturer in Psychology, University of Bedfordshire
Field Application Scientist, Covaris
Senior Lecturer Molecular and Clinical Pharmacology, University of Liverpool
Senior Market Development Manager, Active Motif
UK Reagents Accounts Manager, PerkinElmer
Senior Research Fellow, Brain Tumour Research Centre, Imperial College London
.jpg)
Clinical Professor of Molecular Medicine, Imperial College London
Full Professor, Director of ULB-Cancer Research Center, University of Brussels
